Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyjohns_hopkins: TORe and ESD Coverage Update | Open…
    Ask Trek AI about this page
    Modifiedjohns_hopkins_health_plansPolicy CMS24.21

    Select Endoscopic Procedures (TORe, ESD and related)

    Customize your policy alerts

    Sign up for johns_hopkins_health_plans Policy CMS24.21 alerts

    Get alerted when Policy CMS24.21 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Johns Hopkins Health Plans coverage context, clinical rationale, and coding information for select endoscopic procedures including transoral outlet reduction (TORe) and endoscopic submucosal dissection (ESD); intended for providers and payers applying medical necessity and preauthorization rules.

    Policy Summary
    Payerjohns_hopkins_health_plans
    PolicySelect Endoscopic Procedures (TORe, ESD and related)
    Policy CodePolicy CMS24.21
    Change TypeAdded clinical procedure (ESD) to criteria and background
    Effective DateApr 1, 2026
    Last ReviewJan 20, 2026
    Next Review Date
    Key ActionObtain preauthorization for all inpatient admissions under this policy.
    SourceLink
    POLICY UPDATE CHANGES

    Added Endoscopic submucosal dissection (ESD) to the Policy Criteria section and added the definition and background for ESD.

    Added several keywords.

    12pages (document)
    01/20/2026approval date
    04/01/2026effective date
    07/01/2025

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    supersedes date
    99.89%TORe success
    11.4%TORe adverse events

    Coverage Criteria for Select Endoscopic Procedures

    Indications (descriptive)

    Clinical indications and context described in the policy text (informational in this part of the document):

    TORe Indications: TORe is performed for patients with weight regain and/or dumping syndrome following Roux-en-Y gastric bypass (RYGB); uses endoscopic suturing/anchoring to narrow a dilated gastrojejunal anastomosis and produce increased satiation and weight lossBMI 30–50 kg/m2 noted for FDA authorization of one device; off-label use possible

    Apollo REVISE system was authorized by the FDA in July 2022 for TORe in adults with BMI 30–50 kg/m2 and weight regain after RYGB; TORe may be offered off-label outside this BMI range to treat dumping syndrome.

    ESD Indications: ESD is used to remove large precancerous or early-stage cancerous tumors from the GI tract lining; achieves en-bloc removal by dissecting through the submucosa using a specialized ESD-knifenone

    ESD often preferred over EMR for larger lesions and is the mainstay for gastric dysplasia/early cancer; applicability depends on lesion location and operator expertise; when limited, surgical approach may be favored.

    Use of Endoscopic Submucosal Dissection (ESD) may be constrained by both operator experience and the anatomical location of the lesion. The policy notes that while ESD often achieves en-bloc resection and can be preferable to EMR for larger or high‑risk lesions, limited local expertise or unfavorable lesion location may make a surgical approach the favored option.

    Procedure and Informational Codes

    Informational CPT codesCPT
    43999Unlisted procedure, stomach.
    43499Unlisted procedure, esophagus.
    45399Unlisted procedure, colon.
    43889Gastric restrictive procedure, transoral, endoscopic sleeve gastroplasty (ESG), including argon plasma coagulation, when performed

    Provider Requirements, Prior Authorization, and Billing Notes

    Note

    Preauthorization and coding informational note

    CPT/HCPCS codes listed (CPT 43999, 43499, 45399, 43889) are provided for informational purposes only; inclusion does not guarantee coverage or payment. Benefit coverage is determined by the member's specific benefit plan document and applicable laws. Note that all inpatient admissions require preauthorization.

    • Informational CPT codes do not imply coverage or reimbursement rights.
    • Benefit coverage determined by member’s plan and applicable laws.
    • All inpatient admissions require preauthorization.
    Prior Authorization

    Prior authorization required per plan

    Follow plan-specific prior authorization processes when scheduling covered endoscopic procedures; this policy identifies select procedures covered by Johns Hopkins Health Plans but does not substitute for plan routing requirements.

    • Providers must follow the member’s plan prior authorization procedures.

    Clinical Background and Rationale

    Transoral outlet reduction (TORe) is an endoscopic bariatric revision procedure performed to address weight regain and/or dumping syndrome after Roux‑en‑Y gastric bypass (RYGB). The technique uses endoscopic suturing to narrow a dilated gastrojejunal anastomosis, with reported technical success and outcomes that have been evaluated across multiple time points (3, 6, and 12 months) in the literature.

    Key Definitions

    Dumping syndrome — definition and key features
    DefinitionDumping syndrome: a condition that occurs when food moves too quickly from the stomach into the small intestine, causing symptoms such as nausea, abdominal pain, diarrhea, and sweating.
    Typical clinical contextOccurs after Roux-en-Y gastric bypass (RYGB) and can be related to enlargement of the gastric pouch or dilation of the gastrojejunal anastomosis (stoma).
    Relevance to TOReTransoral outlet reduction (TORe) is performed to treat dumping syndrome by narrowing a dilated gastrojejunal anastomosis, increasing satiation and reducing symptoms and weight regain.
    Associated symptomsNausea, abdominal pain, diarrhea, and sweating.
    Related procedural noteTORe may be offered off-label outside the FDA-authorized BMI range specifically to treat dumping syndrome.
    Policy Summary
    Payerjohns_hopkins_health_plans
    PolicySelect Endoscopic Procedures (TORe, ESD and related)
    Policy CodePolicy CMS24.21
    Change TypeAdded clinical procedure (ESD) to criteria and background
    Effective DateApr 1, 2026
    Last ReviewJan 20, 2026
    Next Review Date
    Key ActionObtain preauthorization for all inpatient admissions under this policy.
    SourceLink
    On This Page
    Coverage Criteria for Select Endoscopic ProceduresProcedure and Informational CodesProvider Requirements, Prior Authorization, and Billing NotesClinical Background and RationaleKey Definitions
  1. Policy lists covered procedures but prior authorization routing is plan-dependent.
  2. Prior Authorization

    Use plan-specific authorization documents (SPDs, COMAR, TRICARE, LCD/NCD)

    Refer to employer- or plan-specific documents (SPDs, COMAR/TRICARE/LCD/NCD) which may supersede or modify authorization pathways; if no plan-specific criteria exist, apply the Medical Policy criteria.

    • Employer Health Programs: follow Summary Plan Description (SPD) when present; otherwise apply Medical Policy criteria.
    • Priority Partners: follow COMAR; if absent, apply Medical Policy criteria.
    • USFHP: TRICARE supersedes JHHP; if no TRICARE policy, apply Medical Policy criteria.
    • Advantage MD and JHHPVA: LCDs/NCDs supersede; if none, apply Medical Policy criteria.
    Step Therapy

    No step therapy specified

    No step therapy requirements are specified in this policy document for the procedures covered; do not impose step therapy unless explicitly required by the member’s benefit plan or applicable guidance.

    Documentation Required

    Monitoring and plan-specific references

    Adherence with this policy may be monitored via post-payment data analysis and/or medical review audits; follow any plan-specific monitoring or reference guidance noted in employer or program documents.

    • Monitoring may include post-payment data analysis and medical review audits.
    • Follow specific program guidance (SPDs, COMAR, TRICARE, LCD/NCD) as applicable.
    Documentation Required

    Policy identification for administrative review (CMS24.21)

    Reference policy identification for administrative review: Policy Number CMS24.21; Effective Date 04/01/2026; Approval Date 01/20/2026 (supersedes 07/01/2025). Include this policy number and dates when submitting for administrative or medical policy review.

    • Policy Number: CMS24.21
    • Effective Date: 04/01/2026
    • Approval Date: 01/20/2026
    • Supersedes Date: 07/01/2025
    Prior Authorization

    Inpatient admission preauthorization required

    All inpatient admissions require preauthorization; obtain preauthorization prior to inpatient admission to avoid denial or delayed payment.

    • Note in coding disclaimer: “All inpatient admissions require preauthorization.”
    Denial Risk

    Claims evaluated per Medical Policy Manual — denial risk if criteria unmet

    Claims submitted under this policy will be evaluated according to the Medical Policy Manual and may be denied if they do not meet the policy's criteria; ensure documentation and authorization meet policy requirements to reduce denial risk.

    • Claims that do not meet the Medical Policy Manual criteria may be denied.
    • Ensure required authorizations and supporting documentation are present before submitting claims.
    Endoscopic submucosal dissection (ESD) — definition
    DefinitionEndoscopic submucosal dissection (ESD) is a minimally invasive procedure using a specialized technique and a modified needle-knife (ESD-knife) to dissect through the submucosa for en-bloc removal of large precancerous or early-stage cancerous tumors from the lining of the digestive tract.
    Primary advantageOften achieves en-bloc (complete) removal of larger tumors, offering higher complete resection and improved disease-free survival compared to EMR.
    LimitationsUse may be limited by available operator expertise and lesion location; in such cases, surgery may be favored.
    Common indicationsLarge precancerous or early-stage cancerous lesions in esophageal, gastric, and colorectal regions where en-bloc resection is desired.
    Endoscopic submucosal dissection (ESD) — addition to Policy Criteria and background
    Policy changeESD was added to the Policy Criteria section and a definition and background for ESD were included in the policy (revision dated 01/20/2026).
    Operational implicationESD is now referenced among select endoscopic procedures considered in the policy; applicability may depend on lesion location and available expertise.
    Background summary includedPolicy background describes ESD as a minimally invasive technique that often achieves en-bloc resection and is preferred for gastric dysplasia/early cancer, with variable outcomes across GI regions.